Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice
Epileptic Disorders · 2026-06 · 28 (3) · 775-785
DOI: 10.1002/epd2.70222 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epileptic Disorders, online erschienen am 27.03.2026. Verfasst von Álvaro Sánchez-Guijo Benavente und 13 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma Bionand), Málaga, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Carbamates, Chlorophenols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Methods
This was a multicenter (six Spanish epilepsy units), retrospective, observational study in patients with drug‐resistant epilepsy who had received treatment with cenobamate as monotherapy (after conversion from polytherapy) or in dual therapy for at least three consecutive months, between April 2017 and November 2024.
Results
In total, 125 patients (mean age 46 ± 15.9 years; median epilepsy duration 16 years, range: 1–65) were included. Median follow‐up was 11 months (range 3–80). Patients had received a median of 5 (range 2–19) previous anti‐seizure medications and were receiving a median of 2 (range 0–3) concomitant anti‐seizure medications at cenobamate initiation; the most common concomitant anti‐seizure medications were lacosamide (36%), brivaracetam (29.6%), and clobazam (26.4%). The median cenobamate dose at the last visit was 200 mg/day (range 100–400 mg/day). By the last visit, 31.5% of patients had achieved seizure freedom, and 75.8%, 58.1%, and 49.2% had achieved ≥50%, ≥75%, and ≥90% reductions in seizure frequency, respectively. During cenobamate treatment, 52% of patients discontinued one, 32% discontinued two, and 4% discontinued three concomitant anti‐seizure medications. In total, 63/125 patients (50.4%) had adverse events during cenobamate treatment, all mild or moderate; 40.8% of patients had adverse events at the last visit. The most reported adverse events were somnolence (22.4%), dizziness (10.4%), fatigue (7.2%), and instability (4.8%). Significance This study highlights the real‐world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug‐resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment‐related adverse events without compromising seizure reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma Bionand), Málaga, Spain.
- Hospital Regional Universitario de Málaga, Servicio de Neurología, Málaga, Spain.
- Hospital Universitario de Jaén, Servicio de Neurología, Jaén, Spain.
- Hospital Regional Universitario de Málaga, Servicio de Neurofisiología, Málaga, Spain.
- Hospital Universitario Reina Sofía, Servicio de Neurología, Córdoba, Spain.
- Hospital Universitario San Cecilio, Servicio de Neurología, Granada, Spain.
ORCID-Profile: Álvaro Sánchez-Guijo Benavente, Guillermina García Martín, Estuardo Daniel Castro Ruiz, Pablo Cabezudo García, Yolanda López Moreno, José Carlos Estévez María, Irene Lorite Fuentes, Sergio Navarro Conti, Raquel Calle Calle, Alejandro Fernández Cabrera, Isabel Ros González, Dulce Campos Blanco, María Isabel Chamorro Muñoz, Pedro Jesús Serrano Castro
Zitieren
APA
Benavente, Á. S., Martín, G. G., Ruiz, E. D. C., García, P. C., Moreno, Y. L., María, J. C. E., Fuentes, I. L., Conti, S. N., Calle, R. C., Cabrera, A. F., González, I. R., Blanco, D. C., Muñoz, M. I. C., & Castro, P. J. S. (2026). Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice. Epileptic Disorders, 28(3), 775-785. https://doi.org/10.1002/epd2.70222
Vancouver
Benavente ÁS, Martín GG, Ruiz EDC, García PC, Moreno YL, María JCE, et al. Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice. Epileptic Disorders. 2026;28(3):775-785. doi:10.1002/epd2.70222
BibTeX
@article{Benavente2026,
author = {Benavente, Álvaro Sánchez-Guijo and Martín, Guillermina García and Ruiz, Estuardo Daniel Castro and García, Pablo Cabezudo and Moreno, Yolanda López and María, José Carlos Estévez and Fuentes, Irene Lorite and Conti, Sergio Navarro and Calle, Raquel Calle and Cabrera, Alejandro Fernández and González, Isabel Ros and Blanco, Dulce Campos and Muñoz, María Isabel Chamorro and Castro, Pedro Jesús Serrano},
title = {Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice},
journal = {Epileptic Disorders},
year = {2026},
volume = {28},
number = {3},
pages = {775--785},
doi = {10.1002/epd2.70222}
}
EUVIMED